Encapsulated Oxovanadium(IV) and Dioxovanadium(V) Complexes into Solid Lipid Nanoparticles Increase Cytotoxicity Against MDA-MB-231 Cell Line

Introduction Solid lipid nanoparticles (SLN) have been considered lately as promising drug delivery system in treatment of many human diseases including cancers. We previously studied potential drug compounds that were effective inhibitors of PTP1B phosphatase – possible target for breast cancer treatment. Based on our studies, two complexes were selected for encapsulation into the SLNs, the compound 1 ([VO(dipic)(dmbipy)] · 2 H2O) and compound 2 ([VOO(dipic)](2-phepyH) · H2O). Here, we investigate the effect of encapsulation of those compounds on cell cytotoxicity against MDA-MB-231 breast cancer cell line. The study also included the stability evaluation of the obtained nanocarriers with incorporated active substances and characterization of their lipid matrix. Moreover, the cell cytotoxicity studies against the MDA-MB-231 breast cancer cell line in comparison and in combination with vincristine have been performed. Wound healing assay was carried out to observe cell migration rate. Methods The properties of the SLNs such as particle size, zeta potential (ZP), and polydispersity index (PDI) were investigated. The morphology of SLNs was observed by scanning electron microscopy (SEM), while the crystallinity of the lipid particles was analyzed by differential scanning calorimetry (DSC) and X-ray diffraction (XRD). The cell cytotoxicity of complexes and their encapsulated forms was carried out against MDA-MB-231 breast cancer cell line using standard MTT protocols. The wound healing assay was performed using live imaging microscopy. Results SLNs with a mean size of 160 ± 25 nm, a ZP of −34.00 ± 0.5, and a polydispersity index of 30 ± 5% were obtained. Encapsulated forms of compounds showed significantly higher cytotoxicity also in co-incubation with vincristine. Moreover, our research shows that the best compound was complex 2 encapsulated into lipid nanoparticles. Conclusion We observed that encapsulation of studied complexes into SLNs increases their cell cytotoxicity against MDA-MB-231 cell line and enhanced the effect of vincristine.

[1]  S. Awale,et al.  Design and synthesis of novel pipernonaline derivatives as anti-austerity agents against human pancreatic cancer PANC-1 cells. , 2022, Bioorganic & medicinal chemistry.

[2]  G. Sulaiman,et al.  Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment , 2022, Molecules.

[3]  M. Kołaczkowski,et al.  Synthesis, In Vitro, and Computational Studies of PTP1B Phosphatase Inhibitors Based on Oxovanadium(IV) and Dioxovanadium(V) Complexes , 2022, International journal of molecular sciences.

[4]  V. Ferretti,et al.  An Overview of Vanadium and Cell Signaling in Potential Cancer Treatments , 2022, Inorganics.

[5]  B. Gawdzik,et al.  Dipicolinate Complexes of Oxovanadium(IV) and Dioxovanadium(V) with 2-Phenylpyridine and 4,4′-Dimethoxy-2,2′-bipyridyl as New Precatalysts for Olefin Oligomerization , 2022, Materials.

[6]  Pei-Jie Chen,et al.  Protein Tyrosine Phosphatase 1B (PTP1B): Insights into Its New Implications in Tumorigenesis. , 2022, Current cancer drug targets.

[7]  I. Nowak,et al.  Synthesis and Potential Applications of Lipid Nanoparticles in Medicine , 2022, Materials.

[8]  C. Patro,et al.  Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery , 2021, Advanced pharmaceutical bulletin.

[9]  M. Kołaczkowski,et al.  Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation , 2021, International journal of molecular sciences.

[10]  B. Gawdzik,et al.  Relationship between Antioxidant Activity and Ligand Basicity in the Dipicolinate Series of Oxovanadium(IV) and Dioxovanadium(V) Complexes , 2021, International journal of molecular sciences.

[11]  G. Sulaiman,et al.  Quercetin against MCF7 and CAL51 breast cancer cell lines: apoptosis, gene expression, and cytotoxicity of nano-quercetin. , 2021, Nanomedicine.

[12]  G. Sulaiman,et al.  Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment , 2021, Pharmaceutics.

[13]  S. S. Kanth,et al.  Interaction of vanadium metal complexes with protein tyrosine phosphatase-1B enzyme along with identification of active site of enzyme by molecular modeling , 2021 .

[14]  G. Barone,et al.  Green Tea Catechins Induce Inhibition of PTP1B Phosphatase in Breast Cancer Cells with Potent Anti-Cancer Properties: In Vitro Assay, Molecular Docking, and Dynamics Studies , 2020, Antioxidants.

[15]  Sebastián Scioli Montoto,et al.  Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects , 2020, Frontiers in Molecular Biosciences.

[16]  G. R. Castro,et al.  Lipid nanoparticles – Metvan: revealing a novel way to deliver a vanadium compound to bone cancer cells , 2019, New Journal of Chemistry.

[17]  J. Tuszynski,et al.  Docosahexaenoic Acid Inhibits PTP1B Phosphatase and the Viability of MCF-7 Breast Cancer Cells , 2019, Nutrients.

[18]  A. Silva,et al.  Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles against different cell lines , 2019, Pharmaceutical development and technology.

[19]  R. Martí,et al.  In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis , 2019, Front. Cell Dev. Biol..

[20]  J. Prados,et al.  Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment , 2019, Nanomaterials.

[21]  I. Alkorta,et al.  Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs , 2019, Nanomaterials.

[22]  M. Górska-Ponikowska,et al.  Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential , 2019, AntiCancer Research.

[23]  Qipeng Zhang,et al.  PTP1B markedly promotes breast cancer progression and is regulated by miR‐193a‐3p , 2018, The FEBS journal.

[24]  J. Tuszynski,et al.  Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2 , 2018, Drug design, development and therapy.

[25]  J. M. Perez-Aguilar,et al.  Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus , 2018, Biological Trace Element Research.

[26]  Wei He,et al.  Redox sensitive lipid‐camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery , 2018, International journal of pharmaceutics.

[27]  M. R. Mozafari,et al.  Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems , 2018, Pharmaceutics.

[28]  M. V. Giuli,et al.  NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest , 2018, Oncogenesis.

[29]  A. Elson.  Stepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases. , 2017, The international journal of biochemistry & cell biology.

[30]  A. Stoker,et al.  Vanadium Compounds as PTP Inhibitors , 2017, Molecules.

[31]  E. Arena,et al.  Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/σ1 selective ligands. , 2017, Colloids and surfaces. B, Biointerfaces.

[32]  N. Durán,et al.  Design, characterization and in vitro evaluation of linalool-loaded solid lipid nanoparticles as potent tool in cancer therapy. , 2017, Colloids and surfaces. B, Biointerfaces.

[33]  E. Briem,et al.  Inhibition of PTP1B disrupts cell–cell adhesion and induces anoikis in breast epithelial cells , 2017, Cell Death & Disease.

[34]  V. Torchilin,et al.  Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models. , 2016, International journal of pharmaceutics.

[35]  J. Kohlbrecher,et al.  Rapamycin-loaded solid lipid nanoparticles: Morphology and impact of the drug loading on the phase transition between lipid polymorphs , 2016 .

[36]  X. Bian,et al.  PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT , 2016, Tumor Biology.

[37]  A. Silva,et al.  Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. , 2014, Colloids and surfaces. B, Biointerfaces.

[38]  Shin Ishii,et al.  Collective Cell Migration , 2013 .

[39]  Wen-jun Zhang,et al.  Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma. , 2012, Biochemical and biophysical research communications.

[40]  K. Hulkower,et al.  Cell Migration and Invasion Assays as Tools for Drug Discovery , 2011, Pharmaceutics.

[41]  R. Müller,et al.  Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. , 2010, Handbook of experimental pharmacology.

[42]  Pieter Wesseling,et al.  Protein tyrosine phosphatases in glioma biology , 2009, Acta Neuropathologica.

[43]  N. Krug,et al.  Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models , 2009, Inhalation toxicology.

[44]  S. Doktorovová,et al.  Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review , 2009 .

[45]  A. Elson,et al.  Protein tyrosine phosphatases: functional inferences from mouse models and human diseases , 2008, The FEBS journal.

[46]  I. G. Fantus,et al.  Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[47]  X. Wu,et al.  Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. , 2007, Advanced drug delivery reviews.

[48]  B. Kennedy,et al.  Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis , 2007, Nature Genetics.

[49]  B. Shekunov,et al.  Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications , 2007, Pharmaceutical Research.

[50]  C. Hellberg,et al.  Protein-tyrosine phosphatases and cancer , 2006, Nature Reviews Cancer.

[51]  Amanda Y. Chan,et al.  Cell migration and invasion assays. , 2005, Methods.

[52]  J. den Hertog,et al.  Redox regulation of protein-tyrosine phosphatases. , 2005, Archives of biochemistry and biophysics.

[53]  G. Giammona,et al.  Solid Lipid Nanoparticles Containing Tamoxifen Characterization and In Vitro Antitumoral Activity , 2005, Drug delivery.

[54]  F. Haj,et al.  Coordinated Regulation of Insulin Signaling by the Protein Tyrosine Phosphatases PTP1B and TCPTP , 2005, Molecular and Cellular Biology.

[55]  K. Pyrzyńska,et al.  Determination of vanadium species in environmental samples. , 2004, Talanta.

[56]  M. Eandi,et al.  Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[57]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[58]  A. Keramidas,et al.  Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents , 1995, Molecular and Cellular Biochemistry.

[59]  C. Xie,et al.  The production and characteristics of solid lipid nanoparticles (SLNs). , 2003, Biomaterials.

[60]  A. Evangelou.  Vanadium in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[61]  C. P. Tan,et al.  Differential scanning calorimetric analysis of edible oils: Comparison of thermal properties and chemical composition , 2000 .

[62]  I. G. Fantus,et al.  Vanadium Compounds Biological Actions and Potential as Pharmacological Agents , 1997, Trends in Endocrinology & Metabolism.

[63]  B. Neel,et al.  The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence , 1992, Cell.

[64]  J. K. Grady,et al.  Characterization of the binding, kinetics, and redox stability of vanadium(IV) and vanadium(V) protein complexes in serum , 1986 .